X4 PharmaceuticalsXFOR +0.61%29 Days Payable is 821.63 as of Mar. 2026, which is 63% below its 10-year median of 2,238.33. GuruFocus rates XFOR with a GF Score™ of 29/100. The stock has 7 warning signs investors should review. Among 708 Biotechnology companies, X4 Pharmaceuticals ranks better than 88.84% on this metric.
The historical rank and industry rank for X4 Pharmaceuticals's Days Payable or its related term are showing as below:
XFOR'
s Days Payable Range Over the Past 10 Years
Min: 453.86 Med: 2238.33 Max: 4022.79
Current: 1543.11
During the past 11 years, X4 Pharmaceuticals's highest Days Payable was 4022.79. The lowest was 453.86. And the median was 2238.33.
XFOR's Days Payable is ranked better than 88.84% of 708
companies
in the Biotechnology industry
Industry Median: 113.56
vs XFOR: 1543.11
X4 Pharmaceuticals's Days Payable
increased
from Mar. 2025 (190.94) to Mar. 2026 (821.63).
It may suggest that X4 Pharmaceuticalsdelayed paying its suppliers.
X4 Pharmaceuticals Days Payable Related Terms
X4 Pharmaceuticals Days Payable Historical Data
* Premium members only.
The historical data trend for X4 Pharmaceuticals's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, X4 Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
X4 Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where X4 Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
X4 Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
X4 Pharmaceuticals (XFOR) has a Days Payable of 821.63 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on X4 Pharmaceuticals and its competitors. This is 63% below median its historical median of 2,238.33. Over the past decade, X4 Pharmaceuticals' Days Payable has ranged from 453.86 to 4,022.79. According to the industry distribution chart, X4 Pharmaceuticals ranks #79 out of 708 companies in the Biotechnology industry, placing it in the top 11.2%.
Is X4 Pharmaceuticals' Days Payable too high?
X4 Pharmaceuticals' current Days Payable of 821.63 is 63% below median its 10-year median of 2,238.33. Over the past 10 years, this metric has ranged from a low of 453.86 to a high of 4,022.79. The Biotechnology industry median Days Payable is 113.56. X4 Pharmaceuticals' value of 821.63 is 623.5% above this industry median. Based on the distribution chart, X4 Pharmaceuticals ranks #79 out of 708 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, X4 Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does X4 Pharmaceuticals' Days Payable compare to ZURA and LYEL?
According to the Biotechnology industry distribution chart, X4 Pharmaceuticals ranks #79 out of 708 companies for Days Payable. This places X4 Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. X4 Pharmaceuticals' value of 821.63 is 623.5% above this benchmark. Historically, X4 Pharmaceuticals' own Days Payable has ranged from 453.86 to 4,022.79 over the past decade. While the company's 10-year median is 2,238.33 vs. the industry median of 113.56, X4 Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. X4 Pharmaceuticals's current Days Payable of 821.63 is 623.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on X4 Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. X4 Pharmaceuticals's current Days Payable is 821.63, which is 63% below median its own 10-year median of 2,238.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is X4 Pharmaceuticals stock overvalued right now?
X4 Pharmaceuticals (XFOR) has a current Days Payable of 821.63. The current Days Payable is 821.63, which is 63% below median its 10-year median of 2,238.33 and 623.5% above the Biotechnology industry median of 113.56. X4 Pharmaceuticals' overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For X4 Pharmaceuticals (XFOR), the current Days Payable is 821.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
29GF Score
Get the complete analysis for XFOR
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XFOR has been successfully added to your 
